Setola
Emanuela Setola, Milano (mi) IT
Patent application number | Description | Published |
---|---|---|
20130289119 | FORMULATION COMPRISING ARGININE, USE AND PREPARATION THEREOF - The present invention relates to an edible formulation comprising the following ingredients (% on mix) 19 to 30 weight % of a dietary supplement comprising at least 50% of L-arginine, 20 to 35 weight % of cereal flakes, 14 to 25 weight % of puffed brown or white rice, 12 to 24 weight % of nuts, 9 to 18 weight % of orange rind (or dried fruit such as cranberries, blueberries, raspberry, blackberry) and 2 to 10 weight % of water and/or fruit juice, its use and process of preparation. | 10-31-2013 |
Roberto Setola, Rome IT
Patent application number | Description | Published |
---|---|---|
20090221927 | APPARATUS AND METHOD FOR VIDEORHINOHYGROMETRIC (VRI) MEASURES - A videorhinohygrometric measuring apparatus ( | 09-03-2009 |
Veronica Setola, Milano IT
Patent application number | Description | Published |
---|---|---|
20090324549 | PROTEINS AND/OR PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES - Proteins and/or peptides originate from the gene which results from the retention of the intron 3 of the gene SMN identified in the gene bank with the access number AY876898 with use for the diagnosis and/or prevention and/or treatment of neurodegenerative diseases. | 12-31-2009 |
Vincent Setola, Ocean Pines, MD US
Patent application number | Description | Published |
---|---|---|
20090203750 | 5-HT2C Receptor Agonists as Anorectic Agents - This invention relates to compounds which modulate receptors of the 5-HT2 family of receptors, and particularly to compounds which modulate 5-HT2C receptors. Compounds of the invention include agonists and selective agonists for the 5-HT2C receptor Compounds of the invention include selective agonists for the 5-HT2C receptor which exhibit significantly less or no agonist activity on the 5-HT2A receptor and/or the 5-HT2B receptor. Compounds of this invention are those of Formula I and pharmaceutically acceptable salts, esters and solvates (including hydrates) wherein variables are defined in the specification hereof. | 08-13-2009 |